New drug VIS954 takes first step: safety check in healthy volunteers
NCT ID NCT06212804
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was the first time a new drug, VIS954, was given to humans. The main goal was to see if it is safe and how the body handles it. 54 healthy adults received either the drug or a placebo. Researchers monitored for side effects and measured drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Visterra Clinical Site
Anaheim, California, 92801, United States